Strait talking: PharmaEngine/BeBetter bring China and Taiwan together in cancer deal
This article was originally published in Scrip
The Republic of China (Taiwan) and the Peoples’ Republic (China) do not see eye to eye on everything but it appears that different nationalistic views are no barrier to pharmaceutical business, as the recently signed research agreement between Taiwan-based PharmaEngine and the new venture BeBetter Medicine Technology in Guangzhou, China illustrates.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.